Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.73 |
| ▸ | DPP4 | P27487 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.73 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.73 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.73 |
| ▸ | GAPDH | P04406 | 1/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.73 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.73 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.73 |
| ▸ | STAT6 | P42226 | 1/20 | 0.73 |
| ▸ | PI4KA | P42356 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.73 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.73 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.73 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4524322 | 1.00 | SLC29A1 (0.73) | SLC29A1DPP4MEN1SLC28A1MAP3K7 | |
| SCHEMBL1682931 | 1.00 | SLC29A1 (0.73) | SLC29A1DPP4MEN1SLC28A1MAP3K7 | |
| SCHEMBL1682932 | 1.00 | SLC29A1 (0.73) | SLC29A1DPP4MEN1SLC28A1MAP3K7 | |
| SCHEMBL20419310 | 1.00 | SLC29A1 (0.73) | SLC29A1DPP4MEN1SLC28A1MAP3K7 | |
| SCHEMBL17612281 | 1.00 | SLC29A1 (0.73) | SLC29A1DPP4MEN1SLC28A1MAP3K7 | |
| SCHEMBL7102267 | 1.00 | SLC29A1 (0.73) | SLC29A1DPP4MEN1SLC28A1MAP3K7 | |
| SCHEMBL23982476 | 1.00 | SLC29A1 (0.73) | SLC29A1DPP4MEN1SLC28A1MAP3K7 | |
| SCHEMBL8214557 | 1.00 | SLC29A1 (0.73) | SLC29A1DPP4MEN1SLC28A1MAP3K7 | |
| SCHEMBL2404574 | 1.00 | SLC29A1 (0.73) | SLC29A1DPP4MEN1SLC28A1MAP3K7 | |
| SCHEMBL2404571 | 1.00 | SLC29A1 (0.73) | SLC29A1DPP4MEN1SLC28A1MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2331115-B3 | PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS | UAB RES FOUND (US) | 2018-12-05 | — | — | EP | disclosed |
| EP-3150220-A1 | PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS | The UAB Research Foundation (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2331115-B1 | PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS | UAB RESEARCH FOUNDATION (US) | 2016-10-05 | — | — | EP | disclosed |
| US-20160022784-A1 | PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS | CORNELL UNIVERSITY | 2016-01-28 | — | — | US | disclosed |
| US-20140199285-A1 | PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS | SOUTHERN RESEARCH INSTITUTE (US) | 2014-07-17 | — | — | US | disclosed |
| US-20110212073-A1 | PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS | THE UAB RESEARCH FOUNDATION (US) | 2011-09-01 | — | — | US | disclosed |
| EP-2331115-A2 | PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS | The UAB Research Foundation (US) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010019954-A9 | PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS | THE UAB RESEARCH FOUNDATION (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010019954-A2 | PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS | THE UAB RESEARCH FOUNDATION (US) | 2010-02-18 | — | — | WO | disclosed |
| US-7488598-B2 | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof | CORNELL CENTER FOR TECHNOLOGY ENTERPRISE AND COMMERCIALIZATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-7037718-B2 | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof | CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| US-20050214901-A1 | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof | CORNELL CENTER FOR TECHNOLOGY, ENTERPRISE & COIMMERCIALIZATION | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050214901-A1 | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof | PNP, UPP1, TYMP | SLC29A1 50/4885DPP4 2366/4885MEN1 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.